Loading...
Market
What will be the outcome of the next Zantac-related court case for GSK?
2
Resolution / Starting Odds
GSK wins • 25%
Plaintiff wins • 25%
Case dismissed • 25%
Settlement reached • 25%
Court records and official announcements from GSK
Story
GSK Wins Chicago Court Case Over Zantac Cancer Claims on Monday
Aug 5, 2024, 09:57 PM
GlaxoSmithKline (GSK) has secured a victory in an Illinois state court as a jury in Chicago found the company not liable for a woman's colorectal cancer on Monday. The case centered around claims that the now-discontinued heartburn drug Zantac caused the illness. This verdict aligns with the scientific consensus that there is no consistent or reliable evidence linking ranitidine, the active ingredient in Zantac, to an increased risk of any cancer. This marks the second consecutive trial win for GSK amidst hundreds of similar lawsuits in Illinois.
View original story
Similar markets
Less than 90% • 25%
90% to 95% • 25%
95% to 99% • 25%
100% • 25%
Decrease by more than 10% • 25%
Decrease by 5% to 10% • 25%
Decrease by less than 5% • 25%
No significant change • 25%
Stock price increases • 25%
Stock price decreases • 25%
Stock price remains stable • 25%
Insufficient data • 25%
Less than $2 billion • 25%
$2 billion to $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
More than $3 billion • 25%
In favor of Bayer AG • 25%
Against Bayer AG • 25%
Settled out of court • 25%
Mistrial • 25%
Less than $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
$3 billion to $3.5 billion • 25%
More than $3.5 billion • 25%